DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Novo Nordisk (NYSE: NVO)

57.54 -0.09 (-0.16%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

NVO $57.54 -0.16%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $57.19
Previous Close $57.63
Daily Range $57.04 - $57.64
52-Week Range $41.72 - $57.70
Market Cap $152.5B
P/E Ratio 0.00
Dividend (Yield) $0.73 (0.9%)
Ex-Dividend Date
Dividend Pay Date
Volume 1,031,980
Average Daily Volume 1,162,242
Current FY EPS $1.85




Drug Makers

Novo Nordisk (NVO) Description

Engaged in discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments - diabetes care and biopharmaceuticals. Website:

News & Commentary Rss Feed

Could Incoming Threats Sink MannKind Corporation?

Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?

Heavy Early Morning Activity On Novo Nordisk A/S (NVO)

4 Reasons Why MannKind Could Succeed Where Pfizer Failed

9 years ago Pfizer tried to launch an inhaled insulin called Exubera to the market and it failed. Here are 4 reasons why Afrezza could succeed where Pfizer came up short.

The Weekender

Trophy Growth Stocks

The Best Company for Investing in the Diabetes Market

Diabetes spending is growing rapidly, and this company is the best way for investors to capitalize on the trend.

Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q1 2015 Results - Earnings Call Transcript

Novo Nordisk (NVO) Beats on Q1 Earnings, Updates Outlook - Analyst Blog

Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE

Novo Nordisk CFO: U.S. Obesity Market Must Emerge, But It Will Take Time

See More NVO News...

NVO's Top Competitors

NVO $57.54 (-0.16%)
Current stock: NVO
JNJ $101.35 (-1.04%)
Current stock: JNJ
PFE $34.28 (-0.23%)
Current stock: PFE
RHHBY $36.83 (-0.94%)
Current stock: RHHBY